Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Clinical trial NCT07633613 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07633613
Sponsor: Centre Antoine Lacassagne
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Non-Small Cell Lung Carcinoma (NSCLC)Metastatic Head and Neck Squamous Cell Carcinoma

Start date: 2026-07-01
Primary completion: 2028-12-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.